Innovating Works

nPL4GBM

Financiado
Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule...
Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM) Glioblastoma (GBM) is considered the highest unmet need in oncology. The average life expectancy of GBM patients is 12-18 months, and the 5-year survival rates remain below 7%. Despite the efforts, the available therapy today coun... Glioblastoma (GBM) is considered the highest unmet need in oncology. The average life expectancy of GBM patients is 12-18 months, and the 5-year survival rates remain below 7%. Despite the efforts, the available therapy today counts only with a few (ineffective) approved therapies. Using a machine learning algorithm, we have discovered a correlation between a small molecule and an unexplored target in GBM. We have developed a hydrogel-based formulation of the molecule with great safety and efficacy in vivo. Our formulation showed 40% long-term survival in a GBM rat model, with complete tumour eradication after a single dose treatment. NANO-PL is a one-time treatment, applied locally during surgery, which is effective even in GBM cells that are resistant to the standard of care or those involved in recurrence. NANO-PL also showed a synergistic efficacy with temozolomide, standard-of-care. The EIC will enable the clinical validation of NANO-PL, completely unlocking the GBM treatment. ver más
28/02/2026
4M€
Duración del proyecto: 23 meses Fecha Inicio: 2024-03-13
Fecha Fin: 2026-02-28

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-13
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
Presupuesto El presupuesto total del proyecto asciende a 4M€
Líder del proyecto
TARGTEX SA No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5